Acknowledgement

This activity is provided by Talem Health and RME Collaborative.

This activity is co-supported by independent medical education grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc.

Credit Available

• Physicians — maximum of 1.5 AMA PRA Category 1 Credits™
• Nurses — 1.5 Contact Hours (1.0 contact hour of pharmacotherapy credit)
• Pharmacists — 1.5 Contact Hours (0.15 CEUs)

All other healthcare professionals completing this course will be issued a statement of participation.

Target Audience

This activity is designed specifically for community oncologists, advanced practice providers, and other members of the healthcare team.

Program Overview

The breast cancer landscape is continuously evolving with rapid advances in research and treatment. Despite ongoing developments, rural and underserved communities face numerous disparities in cancer care due to specialist shortages, long travel distances, and limited resources. Therefore, disseminating the latest information to community oncology clinicians is vital in ensuring access to equitable cancer care. In this panel discussion, three leading experts will share key data on early and metastatic breast cancer from the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Insights on how the findings will impact community practice and strategies to improve breast cancer management in rural and underserved areas will also be discussed.

The content for this enduring activity was recorded on June 4, 2024.

Learning Objectives

Upon completion of this activity, participants should be better able to:  

• Evaluate new data on novel agents and therapeutic strategies for patients with breast cancer
• Discuss how new clinical trial findings may affect treatment of patients with breast cancer
• Apply recently presented data and expert recommendations to optimize care for patients with breast cancer

Faculty

Aditya Bardia, MD, MPH
Professor of Medicine
Director, Breast Oncology Program
UCLA Health Jonsson Comprehensive Cancer Center
Los Angeles, CA

Harold J. Burstein, MD, PhD
Professor of Medicine
Harvard Medical School
Medical Oncologist
Dana-Farber Cancer Institute
Boston, MA

Chris Prakash, MD
Director, Quality Services - Texas Oncology
Chair, Medical Oncology Quality - Texas Oncology
President, Texas Society of Clinical Oncology
Medical Director, Texas Oncology - Paris
Paris, TX

Wade T. Swenson, MD, MPH
Clinical Assistant Professor of Medicine
University of North Dakota
Medical Director
Lakewood Health System
Staples, MN

Joint Accreditation Statement

In support of improving patient care, Talem Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation Statement

Physician Continuing Medical Education
Talem Health designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours. Designated for 1.0 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.

Continuing Pharmacy Education
Talem Health designates this continuing education activity for 1.5 contact hour(s) (0.15 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – JA4008332-0000-24-051-H01-P)
Type of Activity: Application

Disclosure of Conflicts of Interest

Talem Health adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All identified conflicts of interest are thoroughly vetted and mitigated according to Talem Health policy. Talem Health is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

All relevant financial relationships have been mitigated. 

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty

Aditya Bardia, MD, MPH, has disclosed the following relevant financial relationships: consultant/advisory board member for AstraZeneca Pharmaceuticals/Daiichi Sankyo, Inc., Eli Lilly and Company, Genentech, Inc., Gilead Sciences, Inc., Menarini Group, Merck & Co., Inc., and Pfizer, Inc.; contracted research (awarded to institution) from AstraZeneca Pharmaceuticals/Daiichi Sankyo, Inc., Eli Lilly and Company, Genentech, Inc., Gilead Sciences, Inc., Menarini Group, Merck & Co., Inc., and Pfizer, Inc.

Harold J. Burstein, MD, PhD, has no relevant financial relationships to disclose.

Chris Prakash, MD, has disclosed the following relevant financial relationships: speakers’ bureau/honoraria from Myriad Genetics, Inc.

Wade T. Swenson, MD, MPH, has no relevant financial relationships to disclose.

Planners, Managers, and Reviewer 

The Talem Health planners, managers, and reviewer have nothing to disclose.

Instructions for Participation and Credit

This activity is offered at no cost to participants. To receive CME credit, participants must:

1. Read the CME/CE information, including learning objectives and disclosure statements.
2. Complete the pre-test.
3. View the online activity.
4. Complete the post-test and evaluation form.

A post-test score of 67% or higher is required to obtain credit. Your certificate will be made available for immediate download.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

©RME Collaborative, a division of Talem Health, LLC. All Rights Reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Talem Health, LLC is prohibited.

Media

Internet activity

Fee Information

There is no fee for this educational activity.

Contact Information

General Questions
For questions about this activity, please contact RME Collaborative (a division of Talem Health) at 800-913-9370 or cme@cmeruralhealth.com.